Karius

Non-invasive diagnostic tests for infections

Redwood City, California, United States

About Karius

Karius focuses on medical diagnostics for infectious diseases, offering the Karius Test, which detects over 1,000 pathogens from a single blood sample. This non-invasive test is quick and helps clinicians treat hospitalized patients by reducing the need for multiple invasive tests that can delay treatment. The Karius Test utilizes advanced genomics and artificial intelligence to identify microbial cell-free DNA (mcfDNA) in the bloodstream, providing insights into the pathogens responsible for infections. Karius sells these diagnostic tests to healthcare providers, aiming to offer a faster and less invasive alternative to traditional methods, ultimately saving lives and reducing healthcare costs. The company employs proprietary machine learning algorithms to analyze genomic data in real time, continuously updating its reference genome databases to enhance its diagnostic capabilities.

Redwood City, CaliforniaHeadquarters
2014Year Founded
$311.3MTotal Funding
SERIES_CCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Remote Work Options
Hybrid Work Options

Risks

Competition from AlphaFold 3 could overlap with Karius's genomic insights.
Rapid AI advancements by competitors may outpace Karius's technology.
Reliance on continuous funding rounds indicates potential financial instability.

Differentiation

Karius Test detects over 1,000 pathogens from a single blood sample.
The test uses advanced genomics and AI for rapid, non-invasive diagnostics.
Karius's proprietary algorithms analyze genomic data in real time.

Upsides

Karius secured $100M to expand its test beyond 400 U.S. hospitals.
FDA Breakthrough Device Designation boosts credibility and market potential.
Growing demand for non-invasive diagnostics aligns with Karius's offerings.